Results 131 to 140 of about 75,066 (195)

Signaling architecture of the glucagon-like peptide-1 receptor. [PDF]

J Clin Invest
Austin G, Tomas A.
europepmc   +1 more source

BODY‐Q‐7D Measures Consensus‐Based Patient‐Reported Outcomes for the Management of Obesity Treatment

Obesity, EarlyView.
ABSTRACT Objective A global multidisciplinary consensus initiative identified eight patient‐reported outcome domains important in obesity care: self‐esteem; physical, mental, and social health; eating; stigma; body image; and excess skin. Several of these domains are not represented in generic preference‐based measures typically used in weight loss ...
Anne F. Klassen, Charlene Rae, Claire E. E. de Vries, Farmina Dalaei, Manraj N. Kaur, Lucas Gallo, Maarten Hoogbergen, Lotte Poulsen, Andrea L. Pusic, Stefan J. Cano   +9 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists for heart failure with reduced ejection fraction: Is it the next step? [PDF]

ESC Heart Fail
Biegus J.
europepmc   +1 more source

Appetite Suppression by GLP‐1 Receptor Agonists: Role of Delayed Gastric Emptying

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate relationships between delayed gastric emptying and appetite suppression during treatment with liraglutide, a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA). Methods We conducted a secondary data analysis from a 16‐week randomized, placebo‐controlled liraglutide trial in patients with obesity.
Mark I. Friedman, W. Scott Harmsen, Michael Camilleri   +2 more
wiley   +1 more source

Administrative costs of prior authorizations for glucagon-like peptide-1 agonists. [PDF]

J Manag Care Spec Pharm
Pham D, Duby JJ, Setoudeh S, Knox S, Leahy K, Cruz D, Cutler T.   +6 more
europepmc   +1 more source

Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case‐Based Evidence

Obesity, EarlyView.
ABSTRACT Objective Glucagon‐like peptide‐1 receptor agonists are increasingly prescribed for obesity. Although generally considered safe, marked appetite suppression and persistent gastrointestinal adverse effects may increase the risk of nutritional deficiencies.
Janice Bidesie, Erik Oudman
wiley   +1 more source

Glucagon-like Peptide-1 Receptor Agonists and Colorectal Cancer Risk. [PDF]

AACE Endocrinol Diabetes
Winkelman JW, Levine MJ.
europepmc   +1 more source

Trends in Diagnosing Obesity: The CALOR Study

Obesity, EarlyView.
Data from the CALOR study suggest that in people with elevated BMI in the US and Japan, there is underdiagnosis of obesity and a high prevalence of diseases interrelated to obesity. ABSTRACT Objective This study aimed to describe characteristics of people with elevated BMI by presence versus absence of obesity diagnosis and trends over time.
Deborah B. Horn, Eva Lesén, Christen M. Gray, Magnus Bjursell, Hironori Waki   +4 more
wiley   +1 more source

Monogenic and syndromic obesity in children: Clinical recognition, genetics, and precision management

Pediatric Investigation, EarlyView.
Monogenic and syndromic obesity in children often arises from defects in the leptin–melanocortin pathway. Understanding these rare genetic causes not only clarifies mechanisms of appetite regulation but also enables precision therapies, offering hope beyond lifestyle interventions.
Hadel Khalil, Eugene Feigin, Hussein Zaitoon   +2 more
wiley   +1 more source

When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are both common manifestations of ectopic fat accumulation. Although they share multiple risk factors, they also show notable differences in pathological features, standardization of diagnosis, and research maturity.
Yuying Chen, Li Ding, Shan Zhao, Weihong Wang, Jing Zhong, Qiang Yan   +5 more
wiley   +1 more source